The HIV and HBV Therapies Market Report 2022-2032: This report will prove valuable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Factors Such as Rising Prevalence of HIV and HBV, High Investment in R&D, and Growing Government Support Are Driving the Market Growth
Some of the major forces propelling the global HIV and HBV therapies market include rising prevalence of HIV and HBV, high investment in R&D, and growing government support. Robust government support for HIV and HBV therapies research is one of the major factors that propel the market growth. There is a need for significant collaborations among the pharmaceutical industry, foundations, patient advocacy organizations, academic and public researchers and financing programs, regulatory researchers and reimbursement organizations to identify and develop solutions for the unmet diagnostic and therapy requirements. Increasing prevalence of HIV and Hepatitis has urged a need for new treatment options. Hence, government organizations are taking efforts to address the unmet needs and provide advanced care. Major challenge for most of the HIV and HBV therapies in R&D is the large number of investments and research required and the amount of vast clinical aspects of these organisms and diseases. The challenge becomes severed due to the changing nature of antivirals and hence the need for long-term follow-up is crucial. This aspect is predicted to hinder the market over the forecast period.
Regulation Challenges
FDA drug approvals usually involve long and tedious processes before the product is finally commercialized. This usually proves to be a challenge for companies that are involved in intense R&D bringing new products into the market. Safety and usage of the product are completely verified by authorities before commercializing it to the general masses. This requires large amount of investments.
What Questions Should You Ask before Buying a Market Research Report?
• How is the HIV and HBV Therapies market evolving?
• What is driving and restraining the HIV and HBV Therapies market?
• How will each HIV and HBV Therapies submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
• How will the market shares for each HIV and HBV Therapies submarket develop from 2022 to 2032?
• What will be the main driver for the overall market from 2022 to 2032?
• Will leading HIV and HBV Therapies markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
• Who are the leading players and what are their prospects over the forecast period?
• What are the HIV and HBV Therapies projects for these leading companies?
• How will the industry evolve during the period between 2020 and 2032? What are the implications of HIV and HBV Therapies projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the HIV and HBV Therapies market?
• Where is the HIV and HBV Therapies market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product lines?
• What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the HIV and HBV Therapies market today, and over the next 10 years:
• Our 353-page report provides 137 tables, 225 charts, and graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the HIV and HBV Therapies market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
Forecasts to 2032 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising HIV and HBV Therapies prices and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.
Segments Covered in the Report
Drug Class Outlook
• Combination Therapies
• Nucleoside and Non-nucleoside RTIs
• Integrase Inhibitors
• Protease Inhibitors
• Others
Distribution Channel
• Hospital pharmacies
• Retail pharmacies
• Online pharmacies
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for four regional and 20+ leading national markets:
North America
• U.S.
• Canada
Europe
• Germany
• Spain
• United Kingdom
• France
• Italy
• Russia
• Rest of Europe
Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific
LATAM
• Brazil
• Mexico
• Rest of Latin America
MEA
• South Africa
• GCC
• Rest of MEA
Need industry data? Please contact us today.
The report also includes profiles for some of the leading companies in the HIV and HBV Therapies Market, 2022 to 2032, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
• Pfizer
• Merck
• GSK
• AbbVie
• Boehringer Ingelheim
• Gilead Sciences
• Janssen Pharmaceutical
• Teva
• BMS
• Arbustus Biopharma
Overall world revenue for HIV and HBV Therapies Market, 2022 to 2032 in terms of value the market will surpass US$36.2 billion in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the HIV and HBV Therapies Market, 2022 to 2032 report help you?
In summary, our 350+ page report provides you with the following knowledge:
• Revenue forecasts to 2032 for HIV and HBV Therapies Market, 2022 to 2032 Market, with forecasts for drug class, distribution channel, and company size, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2032 for four regional and 20 key national markets – See forecasts for the HIV and HBV Therapies Market, 2022 to 2032 market in North America, Europe, Asia-Pacific and LAMEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, Spain, Russia, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market – including company profiles for 10 of the major companies involved in the HIV and HBV Therapies Market, 2022 to 2032.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the HIV and HBV Therapies Market, 2022 to 2032, market-leading companies. You will find data, trends and predictions.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today HIV and HBV Therapies Market Report 2022-2032: Forecasts by Drug Class (Combination Therapies, Nucleoside and Non-nucleoside RTIs, Integrase Inhibitors, Protease Inhibitors, Others), by Distribution channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: contactus@visiongain.com
1. Report Overview
1.1 Objectives of the Study
1.2 Introduction to HIV and HBV Therapies Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered By This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2 Executive Summary
2.1 Geographical Snapshot: Global HIV and HBV Therapies Market
2.2 Drug Class Segment: Market Attractiveness Index
2.3 Distribution Channel Segment: Market Attractiveness Index
3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.2 Market Restraining Factors
3.2.3 Market Opportunities
3.3 COVID-19 Impact Analysis
3.4 Porter’s Five Forces Analysis
3.4.1 Supplier Power
3.4.2 Buyer Power
3.4.3 Competitive Rivalry
3.4.4 Threat from Substitutes
3.4.5 Threat of New Entrants
4 Global HIV and HBV Therapies Market Analysis by Drug Class
4.1 Key Findings
4.2 Drug Class Segment Growth Prospects
4.3 Global HIV and HBV Therapies Market Size Estimation and Forecast by Drug Class
4.4 Combination Therapies
4.4.1 Combination Therapies Market Forecast by Region, 2022-2032 (US$ Bn)
4.4.2 Combination Therapies Market Share by Region, 2022-2032 (%)
4.5 Nucleoside and Non-nucleoside RTIs
4.5.1 Nucleoside and Non-nucleoside RTIs Market Forecast by Region, 2022-2032 (US$ Bn)
4.5.2 Nucleoside and Non-nucleoside RTIs Market Share by Region, 2022-2032 (%)
4.6 Integrase Inhibitors
4.6.1 Integrase inhibitors Market Forecast by Region, 2022-2032 (US$ Bn)
4.6.2 Integrase inhibitors Market Share by Region, 2022-2032 (%)
4.7 Protease Inhibitors
4.7.1 Protease Inhibitors Market Forecast by Region, 2022-2032 (US$ Bn)
4.7.2 Protease Inhibitors Market Share by Region, 2022-2032 (%)
4.8 Other Drug class
4.8.1 Other Drug Class Market Forecast by Region, 2022-2032 (US$ Bn)
4.8.2 Other Drug Class Market Share by Region, 2022-2032 (%)
5 Global HIV and HBV Therapies Market Analysis by Distribution Channel
5.1 Key Findings
5.2 Distribution Channel Segment Growth Prospects
5.3 Global HIV and HBV Therapies Market Size Estimation and Forecast by Distribution Channel
5.4 Global HIV and HBV Therapies Market Share by Distribution Channel, 2022 & 2032
5.5 Hospital Pharmacies
5.5.1 Hospital pharmacies Market Forecast by Region, 2022-2032 (US$ Bn)
5.5.2 Hospital pharmacies Market Share by Region, 2022-2032 (%)
5.6 Retail Pharmacies
5.6.1 Retail pharmacies Market Forecast by Region, 2022-2032 (US$ Bn)
5.6.2 Retail pharmacies Market Share by Region, 2022-2032 (%)
5.7 Online Pharmacies
5.7.1 Online Pharmacies Market Forecast by Region, 2022-2032 (US$ Bn)
5.7.2 Online Pharmacies Market Share by Region, 2022-2032 (%)
6 Global HIV and HBV Therapies Market Pipeline Analysis
6.1 Key Findings
6.2 HIV Pipeline
6.3 HBV Pipeline
7 Global HIV and HBV Therapies Market Analysis by Region
7.1 Key Findings
7.2 Regional Market Size Estimation and Forecast
7.3 COVID-19 Impact Analysis: Recovery Scenarios (V, U, W, L)
8 North America HIV and HBV Therapies Market Analysis
8.1 Key Findings
8.2 North America HIV and HBV Therapies Market Attractiveness Index
8.3 North America HIV and HBV Therapies Market by Country, 2022, 2027 & 2032 (US$ bn)
8.4 North America HIV and HBV Therapies Market Size Estimation and Forecast by Country
8.5 North America HIV and HBV Therapies Market Size Estimation and Forecast by Drug Class
8.6 North America HIV and HBV Therapies Market Size Estimation and Forecast by Distribution Channel
8.7 U.S.
8.7.1 U.S. HIV and HBV Therapies Market by Drug Class
8.7.2 U.S. HIV and HBV Therapies Market by Distribution Channel
8.8 Canada
8.8.1 Canada HIV and HBV Therapies Market by Drug Class
8.8.2 Canada HIV and HBV Therapies Market by Distribution Channel
9 Europe HIV and HBV Therapies Market Analysis
9.1 Key Findings
9.2 Europe HIV and HBV Therapies Market Attractiveness Index
9.3 Europe HIV and HBV Therapies Market by Country, 2022, 2027 & 2032 (US$ bn)
9.4 Europe HIV and HBV Therapies Market Size Estimation and Forecast by Country
9.5 Europe HIV and HBV Therapies Market Size Estimation and Forecast by Drug Class
9.6 Europe HIV and HBV Therapies Market Size Estimation and Forecast by Distribution Channel
9.7 Germany
9.7.1 Germany HIV and HBV Therapies Market by Drug Class
9.7.2 Germany HIV and HBV Therapies Market by Distribution Channel
9.8 U.K.
9.8.1 U.K. HIV and HBV Therapies Market by Drug Class
9.8.2 U.K. HIV and HBV Therapies Market by Distribution Channel
9.9 France
9.9.1 France HIV and HBV Therapies Market by Drug Class
9.9.2 France HIV and HBV Therapies Market by Distribution Channel
9.10 Italy
9.10.1 Italy HIV and HBV Therapies Market by Drug Class
9.10.2 Italy HIV and HBV Therapies Market by Distribution Channel
9.11 Spain
9.11.1 Spain HIV and HBV Therapies Market by Drug Class
9.11.2 Spain HIV and HBV Therapies Market by Distribution Channel
9.12 Russia
9.12.1 Russia HIV and HBV Therapies Market by Drug Class
9.12.2 Russia HIV and HBV Therapies Market by Distribution Channel
9.13 Rest of Europe
9.13.1 Rest of Europe HIV and HBV Therapies Market by Drug Class
9.13.2 Rest of Europe HIV and HBV Therapies Market by Distribution Channel
10 Asia Pacific HIV and HBV Therapies Market Analysis
10.1 Key Findings
10.2 Asia Pacific HIV and HBV Therapies Market Attractiveness Index
10.3 Asia Pacific HIV and HBV Therapies Market by Country, 2022, 2027 & 2032 (US$ bn)
10.4 Asia Pacific HIV and HBV Therapies Market Size Estimation and Forecast by Country
10.5 Asia Pacific HIV and HBV Therapies Market Size Estimation and Forecast by Drug Class
10.6 Asia Pacific HIV and HBV Therapies Market Size Estimation and Forecast by Distribution Channel
10.7 Japan
10.7.1 Japan HIV and HBV Therapies Market by Drug Class
10.7.2 Japan HIV and HBV Therapies Market by Distribution Channel
10.8 China
10.8.1 China HIV and HBV Therapies Market by Drug Class
10.8.2 China HIV and HBV Therapies Market by Distribution Channel
10.9 India
10.9.1 India HIV and HBV Therapies Market by Drug Class
10.9.2 India HIV and HBV Therapies Market by Distribution Channel
10.10 South Korea
10.10.1 South Korea HIV and HBV Therapies Market by Drug Class
10.10.2 South Korea HIV and HBV Therapies Market by Distribution Channel
10.11 Australia
10.11.1 Australia HIV and HBV Therapies Market by Drug Class
10.11.2 Australia HIV and HBV Therapies Market by Distribution Channel
10.12 Rest of APAC
10.12.1 Rest of APAC HIV and HBV Therapies Market by Drug Class
10.12.2 Rest of APAC HIV and HBV Therapies Market by Distribution Channel
11 Latin America HIV and HBV Therapies Market Analysis
11.1 Key Findings
11.2 Latin America HIV and HBV Therapies Market Attractiveness Index
11.3 Latin America HIV and HBV Therapies Market by Country, 2022, 2027 & 2032 (US$ bn)
11.4 Latin America HIV and HBV Therapies Market Size Estimation and Forecast by Country
11.5 Latin America HIV and HBV Therapies Market Size Estimation and Forecast by Drug Class
11.6 Latin America HIV and HBV Therapies Market Size Estimation and Forecast by Distribution Channel
11.7 Brazil
11.7.1 Brazil HIV and HBV Therapies Market by Drug Class
11.7.2 Brazil HIV and HBV Therapies Market by Distribution Channel
11.8 Mexico
11.8.1 Mexico HIV and HBV Therapies Market by Drug Class
11.8.2 Mexico HIV and HBV Therapies Market by Distribution Channel
11.9 Rest of Latin America
11.9.1 Rest of LATAM HIV and HBV Therapies Market by Drug Class
11.9.2 Rest of LATAM HIV and HBV Therapies Market by Distribution Channel
12 MEA HIV and HBV Therapies Market Analysis
12.1 Key Findings
12.2 MEA HIV and HBV Therapies Market Attractiveness Index
12.3 MEA HIV and HBV Therapies Market by Country, 2022, 2027 & 2032 (US$ bn)
12.4 MEA HIV and HBV Therapies Market Size Estimation and Forecast by Country
12.5 MEA HIV and HBV Therapies Market Size Estimation and Forecast by Drug Class
12.6 MEA HIV and HBV Therapies Market Size Estimation and Forecast by Distribution Channel
12.7 South Africa
12.7.1 South Africa HIV and HBV Therapies Market by Drug Class
12.7.2 South Africa HIV and HBV Therapies Market by Distribution Channel
12.8 GCC
12.8.1 GCC HIV and HBV Therapies Market by Drug Class
12.8.2 GCC HIV and HBV Therapies Market by Distribution Channel
12.9 Rest of MEA
12.9.1 Rest of MEA HIV and HBV Therapies Market by Drug Class
12.9.2 Rest of MEA HIV and HBV Therapies Market by Distribution Channel
13 Competitive Landscape
13.1 Company Share Analysis
13.2 Key Business Strategy Analysis
14 Company Profiles
14.1 Pfizer
14.1.1 Company Snapshot
14.1.2 Company Overview
14.1.3 Financial Analysis
14.1.4 Product Benchmarking
14.1.5 Strategic Outlook
14.2 Merck
14.2.1 Company Snapshot
14.2.2 Company Overview
14.2.3 Financial Analysis
14.2.4 Product Benchmarking
14.2.5 Strategic Outlook
14.3 GSK
14.3.1 Company Snapshot
14.3.2 Company Overview
14.3.3 Financial Analysis
14.3.4 Product Benchmarking
14.3.5 Strategic Outlook
14.4 AbbVie
14.4.1 Company Snapshot
14.4.2 Company Overview
14.4.3 Financial Analysis
14.4.4 Product Benchmarking
14.4.5 Strategic Outlook
14.5 Boehringer Ingelheim
14.5.1 Company Snapshot
14.5.2 Company Overview
14.5.3 Financial Analysis
14.5.4 Product Benchmarking
14.5.5 Strategic Outlook
14.6 Gilead Sciences
14.6.1 Company Snapshot
14.6.2 Company Overview
14.6.3 Financial Analysis
14.6.4 Product Benchmarking
14.6.5 Strategic Outlook
14.7 Janssen Pharma
14.7.1 Company Snapshot
14.7.2 Company Overview
14.7.3 Financial Analysis
14.7.4 Product Benchmarking
14.7.5 Strategic Outlook
14.8 Teva
14.8.1 Company Snapshot
14.8.2 Company Overview
14.8.3 Financial Analysis
14.8.4 Product Benchmarking
14.8.5 Strategic Outlook
14.9 BMS
14.9.1 Company Snapshot
14.9.2 Company Overview
14.9.3 Financial Analysis
14.9.4 Product Benchmarking
14.9.5 Strategic Outlook
14.10 Arbutus Biopharma
14.10.1 Company Snapshot
14.10.2 Company Overview
14.10.3 Financial Analysis
14.10.4 Product Benchmarking
14.10.5 Strategic Outlook
15 Conclusion and Recommendations
15.1 Concluding Remarks from Visiongain
15.2 Recommendations for Market Players
List of Tables
Table 1 Global HIV and HBV Therapies Market Snapshot, 2022 & 2032 (US$ billion, CAGR %)
Table 2 HIV and HBV Therapies Market, By Region, 2022-2032 (US$ Bn, AGR %, CAGR %) (V-shaped Recovery)
Table 3 HIV and HBV Therapies Market, By Region, 2022-2032 (US$ Bn, AGR %, CAGR %) (U-shaped Recovery)
Table 4 HIV and HBV Therapies Market, By Region, 2022-2032 (US$ Bn, AGR %, CAGR %) (W-shaped Recovery)
Table 5 HIV and HBV Therapies Market, By Region, 2022-2032 (US$ Bn, AGR %, CAGR %) (L-shaped Recovery)
Table 6 HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 7 Approved Combination Therapies
Table 8 Combination Therapies Market, by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 9 Approved NRTIs
Table 10 Approved NNRTIs
Table 11 Nucleoside and Non-nucleoside RTIs Market, by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 12 Approved Integrase Inhibitors
Table 13 Integrase Inhibitors Market, by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 14 Approved Protease Inhibitors
Table 15 Protease Inhibitors Market, by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 16 Approved other therapies
Table 17 Other Drug Class Market, by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 18 HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 19 Hospital pharmacies Market, by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 20 Retail pharmacies Market, by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 21 Online pharmacies Market, by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 22 HIV Pipeline Products
Table 23 HIV Pipeline Products (bNAbs)
Table 24 HIV Pipeline Products (other compounds)
Table 25 Chronic Hepatitis B pipeline, 2022
Table 26 HIV and HBV Therapies Market, By Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 27 HIV and HBV Therapies Market, By Region, 2022-2032 (US$ Bn, AGR %, CAGR %) (V-shaped Recovery)
Table 28 HIV and HBV Therapies Market, By Region, 2022-2032 (US$ Bn, AGR %, CAGR %) (U-shaped Recovery)
Table 29 HIV and HBV Therapies Market, By Region, 2022-2032 (US$ Bn, AGR %, CAGR %) (W-shaped Recovery)
Table 30 HIV and HBV Therapies Market, By Region, 2022-2032 (US$ Bn, AGR %, CAGR %) (L-shaped Recovery)
Table 31 North America HIV and HBV Therapies Market, By Country, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 32 North America HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 33 North America HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 34 US HIV and HBV Therapies Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 35 US HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 36 US HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 37 Canada HIV and HBV Therapies Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 38 Canada HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 39 Canada HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 40 Europe HIV and HBV Therapies Market, By Country, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 41 Europe HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 42 Europe HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 43 Germany HIV and HBV Therapies Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 44 Germany HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 45 Germany HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 46 UK HIV and HBV Therapies Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 47 UK HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 48 UK HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 49 France HIV and HBV Therapies Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 50 France HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 51 France HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 52 Italy HIV and HBV Therapies Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 53 Italy HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 54 Italy HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 55 Spain HIV and HBV Therapies Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 56 Spain HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 57 Spain HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 58 Russia HIV and HBV Therapies Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 59 Russia HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 60 Russia HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 61 Rest of Europe HIV and HBV Therapies Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 62 Rest of Europe HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 63 Rest of Europe HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 64 Asia Pacific HIV and HBV Therapies Market, By Country, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 65 Asia Pacific HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 66 Asia Pacific HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 67 Japan HIV and HBV Therapies Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 68 Japan HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 69 Japan HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 70 China HIV and HBV Therapies Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 71 China HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 72 China HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 73 India HIV and HBV Therapies Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 74 India HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 75 India HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 76 South Korea HIV and HBV Therapies Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 77 South Korea HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 78 South Korea HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 79 Australia HIV and HBV Therapies Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 80 Australia HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 81 Australia HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 82 Rest of Asia Pacific HIV and HBV Therapies Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 83 Rest of Asia Pacific HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 84 Rest of Asia Pacific HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 85 Latin America HIV and HBV Therapies Market, By Country, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 86 Latin America HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 87 Latin America HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 88 Brazil HIV and HBV Therapies Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 89 Brazil HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 90 Brazil HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 91 Mexico HIV and HBV Therapies Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 92 Mexico HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 93 Mexico HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 94 Rest of Latin America HIV and HBV Therapies Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 95 Rest of LATAM HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 96 Rest of LATAM HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 97 MEA HIV and HBV Therapies Market, By Country, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 98 MEA HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 99 MEA HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 100 South Africa HIV and HBV Therapies Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 101 South Africa HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 102 South Africa HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 103 GCC HIV and HBV Therapies Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 104 GCC HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 105 GCC HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 106 Rest of MEA HIV and HBV Therapies Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 107 Rest of MEA HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 108 Rest of MEA HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Table 109 Key Business Strategies Adopted by Key Players in Global HIV and HBV Therapies Market
Table 110 Pfizer: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 111 Pfizer: Product Benchmarking
Table 112 Merck: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 113 Merck: Product Benchmarking
Table 114 Merck: Strategic Outlook
Table 115 GSK: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 116 GSK: Product Benchmarking
Table 117 GSK: Strategic Outlook
Table 118 AbbVie: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website)
Table 119 AbbVie: Product Benchmarking
Table 120 AbbVie: Strategic Outlook
Table 121 Boehringer Ingelheim: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 122 Boehringer Ingelheim: Product Benchmarking
Table 123 Gilead Sciences: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 124 Gilead Sciences: Product Benchmarking
Table 125 Gilead Sciences: Strategic Outlook
Table 126 Janssen Pharma: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 127 Janssen Pharma: Product Benchmarking
Table 128 Janssen Pharma: Strategic Outlook
Table 129 Teva: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 130 Teva: Product Benchmarking
Table 131 Teva: Strategic Outlook
Table 132 BMS: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website)
Table 133 BMS: Product Benchmarking
Table 134 BMS: Strategic Outlook
Table 135 Arbutus Biopharma: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website)
Table 136 ARBUTUS BIOPHARMA: Product Benchmarking
Table 137 ARBUTUS BIOPHARMA: Strategic Outlook
List of Figures
Figure 1 Global HIV and HBV Therapies Market Segmentation
Figure 2 Global HIV and HBV Therapies Market Forecast by Region: Market Attractiveness Index
Figure 3 Global HIV and HBV Therapies Market by Drug Class: Market Attractiveness Index
Figure 4 Global HIV and HBV Therapies Market by Distribution Channel: Market Attractiveness Index
Figure 5 Global HIV and HBV Therapies Market: Market Dynamics
Figure 6 Global COVID Impact Analysis: HIV and HBV Therapies Market Recovery Scenarios
Figure 7 Global HIV and HBV Therapies Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): “V” Shaped Recovery
Figure 8 Global HIV and HBV Therapies Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): “U” Shaped Recovery
Figure 9 Global HIV and HBV Therapies Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): “W” Shaped Recovery
Figure 10 Global HIV and HBV Therapies Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): “L” Shaped Recovery
Figure 11 Global HIV and HBV Therapies Market: Porter’s Five Forces Analysis
Figure 12 Global HIV and HBV Therapies Market Forecast by Drug Class 2022, 2027, 2032 (Revenue, CAGR%)
Figure 13 Global HIV and HBV Therapies Market Share Forecast by Drug Class, 2022, 2027, 2032 (%)
Figure 14 Global HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
Figure 15 Combination Therapies Market Forecast by Region, 2022-2032 (US$ billion)
Figure 16 Combination Therapies Market Share Forecast by Region, 2022-2032 (%)
Figure 17 Nucleoside and Non-nucleoside RTIs Market Forecast by Region, 2022-2032 (US$ billion)
Figure 18 Nucleoside and Non-nucleoside RTIs Market Share Forecast by Region, 2022-2032 (%)
Figure 19 Integrase inhibitors Market Forecast by Region, 2022-2032 (US$ billion)
Figure 20 Integrase inhibitors Market Share Forecast by Region, 2022-2032 (%)
Figure 21 Protease Inhibitors Market Forecast by Region, 2022-2032 (US$ billion)
Figure 22 Protease Inhibitors Market Share Forecast by Region, 2022-2032 (%)
Figure 23 Other Drug Class Market Forecast by Region, 2022-2032 (US$ billion)
Figure 24 Other Drug Class Market Share Forecast by Region, 2022-2032 (%)
Figure 25 Global HIV and HBV Therapies Market Forecast by Distribution Channel 2022, 2027, 2032 (Revenue, CAGR%)
Figure 26 Global HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
Figure 27 Global HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022, 2032 (%)
Figure 28 Hospital pharmacies Market Forecast by Region, 2022-2032 (US$ billion)
Figure 29 Hospital pharmacies Market Share Forecast by Region, 2022-2032 (%)
Figure 30 Retail pharmacies Market Forecast by Region, 2022-2032 (US$ billion)
Figure 31 Retail pharmacies Market Share Forecast by Region, 2022-2032 (%)
Figure 32 Online Pharmacies Market Forecast by Region, 2022-2032 (US$ billion)
Figure 33 Online Pharmacies Market Share Forecast by Region, 2022-2032 (%)
Figure 34 Global HIV and HBV Therapies Market Forecast by Region 2022, 2027, 2032 (Revenue), C
Figure 35 Global HIV and HBV Therapies Market Share Forecast by Region 2022, 2027, 2032(%)
Figure 36 Global HIV and HBV Therapies Market by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
Figure 37 Global HIV and HBV Therapies Market by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%)): “V” Shaped Recovery
Figure 38 Global HIV and HBV Therapies Market by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%)): “U” Shaped Recovery
Figure 39 Global HIV and HBV Therapies Market by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%)): “W” Shaped Recovery
Figure 40 Global HIV and HBV Therapies Market by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%)): “L” Shaped Recovery
Figure 41 North America HIV and HBV Therapies Market Attractiveness Index
Figure 42 North America HIV and HBV Therapies Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 43 North America HIV and HBV Therapies Market Forecast by Country, 2022-2032 (US$ billion, AGR %)
Figure 44 North America HIV and HBV Therapies Market Share Forecast by Country, 2022 & 2032 (%)
Figure 45 North America HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
Figure 46 North America HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
Figure 47 North America HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
Figure 48 North America HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
Figure 49 U.S. HIV and HBV Therapies Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 50 U.S. HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
Figure 51 U.S. HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
Figure 52 U.S. HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
Figure 53 U.S. HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
Figure 54 Canada HIV and HBV Therapies Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 55 Canada HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
Figure 56 Canada HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
Figure 57 Canada HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
Figure 58 Canada HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
Figure 59 Europe HIV and HBV Therapies Market Attractiveness Index
Figure 60 Europe HIV and HBV Therapies Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 61 Europe HIV and HBV Therapies Market Forecast by Country, 2022-2032 (US$ billion, AGR %)
Figure 62 Europe HIV and HBV Therapies Market Share Forecast by Country, 2022 & 2032 (%)
Figure 63 Europe HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
Figure 64 North America HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
Figure 65 Europe HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
Figure 66 Europe HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
Figure 67 Germany HIV and HBV Therapies Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 68 Germany HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
Figure 69 Germany HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
Figure 70 Germany HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
Figure 71 Germany HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
Figure 72 UK HIV and HBV Therapies Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 73 U.K. HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
Figure 74 U.K. HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
Figure 75 U.K. HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
Figure 76 U.K. HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
Figure 77 France HIV and HBV Therapies Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 78 France HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
Figure 79 France HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
Figure 80 France HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
Figure 81 France HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
Figure 82 Italy HIV and HBV Therapies Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 83 Italy HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
Figure 84 Italy HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
Figure 85 Italy HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
Figure 86 Italy HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
Figure 87 Spain HIV and HBV Therapies Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 88 Spain HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
Figure 89 Spain HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
Figure 90 Spain HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
Figure 91 Spain HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
Figure 92 Russia HIV and HBV Therapies Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 93 Russia HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
Figure 94 Russia HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
Figure 95 Russia HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
Figure 96 Russia HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
Figure 97 Rest of Europe HIV and HBV Therapies Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 98 Rest of Europe HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
Figure 99 Rest of Europe HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
Figure 100 Rest of Europe HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
Figure 101 Rest of Europe HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
Figure 102 Asia Pacific HIV and HBV Therapies Market Attractiveness Index
Figure 103 Asia Pacific HIV and HBV Therapies Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 104 Asia Pacific HIV and HBV Therapies Market Forecast by Country, 2022-2032 (US$ billion, AGR %)
Figure 105 Asia Pacific HIV and HBV Therapies Market Share Forecast by Country, 2022 & 2032 (%)
Figure 106 Asia Pacific HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
Figure 107 Asia Pacific HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
Figure 108 Asia Pacific HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
Figure 109 Asia Pacific HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
Figure 110 Japan HIV and HBV Therapies Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 111 Japan HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
Figure 112 Japan HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
Figure 113 Japan HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
Figure 114 Japan HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
Figure 115 China HIV and HBV Therapies Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 116 China HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
Figure 117 China HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
Figure 118 China HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
Figure 119 China HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
Figure 120 India HIV and HBV Therapies Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 121 India HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
Figure 122 India HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
Figure 123 India HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
Figure 124 India HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
Figure 125 South Korea HIV and HBV Therapies Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 126 South Korea HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
Figure 127 South Korea HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
Figure 128 South Korea HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
Figure 129 South Korea HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
Figure 130 Australia HIV and HBV Therapies Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 131 Australia HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
Figure 132 Australia HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
Figure 133 Australia HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
Figure 134 Australia HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
Figure 135 Rest of Asia Pacific HIV and HBV Therapies Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 136 Rest of APAC HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
Figure 137 Rest of APAC HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
Figure 138 Rest of APAC HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
Figure 139 Rest of APAC HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
Figure 140 Latin America HIV and HBV Therapies Market Attractiveness Index
Figure 141 Latin America HIV and HBV Therapies Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 142 Latin America HIV and HBV Therapies Market Forecast by Country, 2022-2032 (US$ billion, AGR %)
Figure 143 Latin America HIV and HBV Therapies Market Share Forecast by Country, 2022 & 2032 (%)
Figure 144 Latin America HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
Figure 145 Latin America HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
Figure 146 Latin America HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
Figure 147 Latin America HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
Figure 148 Brazil HIV and HBV Therapies Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 149 Brazil HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
Figure 150 Brazil HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
Figure 151 Brazil HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
Figure 152 Brazil HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
Figure 153 Mexico HIV and HBV Therapies Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 154 Mexico HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
Figure 155 Mexico HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
Figure 156 Mexico HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
Figure 157 Mexico HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
Figure 158 Rest of LATAM HIV and HBV Therapies Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 159 Rest of LATAM HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
Figure 160 Rest of LATAM HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
Figure 161 Rest of LATAM HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
Figure 162 Rest of LATAM HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
Figure 163 MEA HIV and HBV Therapies Market Attractiveness Index
Figure 164 MEA HIV and HBV Therapies Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 165 MEA HIV and HBV Therapies Market Forecast by Country, 2022-2032 (US$ billion, AGR %)
Figure 166 MEA HIV and HBV Therapies Market Share Forecast by Country, 2022 & 2032 (%)
Figure 167 MEA HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
Figure 168 MEA HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
Figure 169 MEA HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
Figure 170 MEA HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
Figure 171 South Africa HIV and HBV Therapies Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 172 South Africa HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
Figure 173 South Africa HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
Figure 174 South Africa HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
Figure 175 South Africa HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
Figure 176 GCC HIV and HBV Therapies Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 177 GCC HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
Figure 178 GCC HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
Figure 179 GCC HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
Figure 180 GCC HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
Figure 181 Rest of MEA HIV and HBV Therapies Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 182 Rest of MEA HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
Figure 183 Rest of MEA HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
Figure 184 Rest of MEA HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
Figure 185 Rest of MEA HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
Figure 186 Global HIV and HBV Therapies Market: Company Share Analysis, 2021
Figure 187 Pfizer: Net Revenue, 2019-2021 (US$ million, AGR %)
Figure 188 Pfizer: Regional Market Shares, 2021
Figure 189 Pfizer: Gross Profit, 2019-2021 (US$ million, AGR %)
Figure 190 Pfizer: R&D, 2019-2021 (US$ million, AGR %)
Figure 191 Merck: Net Revenue, 2019-2021 (US$ million, AGR %)
Figure 192 Merck: Regional Market Shares, 2021
Figure 193 Merck: Income from Continuing Operations before Taxes, 2019-2021 (US$ million, AGR %)
Figure 194 Merck: R&D, 2019-2021 (US$ million, AGR %)
Figure 195 GSK: Net Revenue, 2019-2021 (US$ million, AGR %)
Figure 196 GSK: Regional Market Shares, 2021
Figure 197 GSK: Gross Profit, 2019-2021 (US$ million, AGR %)
Figure 198 GSK: R&D, 2019-2021 (US$ million, AGR %)
Figure 199 AbbVie: Net Revenue, 2019-2021 (US$ million, AGR %)
Figure 200 AbbVie: Regional Market Shares, 2021
Figure 201 AbbVie: Operating Earnings, 2019-2021 (US$ million, AGR %)
Figure 202 AbbVie: R&D, 2019-2021 (US$ million, AGR %)
Figure 203 Boehringer Ingelheim: Net Revenue, 2019-2021 (US$ million, AGR %)
Figure 204 Boehringer Ingelheim: Regional Market Shares, 2021
Figure 205 Boehringer Ingelheim: Operating Income, 2019-2021 (US$ million, AGR %)
Figure 206 Boehringer Ingelheim: R&D, 2019-2021 (US$ million, AGR %)
Figure 207 Gilead Sciences: Net Revenue, 2019-2021 (US$ million, AGR %)
Figure 208 Gilead Sciences: Regional Market Shares, 2021
Figure 209 Gilead Sciences: Operating Profit, 2019-2021 (US$ million, AGR %)
Figure 210 Gilead Sciences: R&D, 2019-2021 (US$ million, AGR %)
Figure 211 Janssen Pharma: Net Revenue, 2019-2021 (US$ million, AGR %)
Figure 212 Janssen Pharma: Regional Market Shares, 2021
Figure 213 Janssen Pharma: Gross Profit, 2019-2021 (US$ million, AGR %)
Figure 214 Janssen Pharma: R&D, 2019-2021 (US$ million, AGR %)
Figure 215 Teva: Net Revenue, 2019-2021 (US$ million, AGR %)
Figure 216 Teva: Regional Market Shares, 2021
Figure 217 Teva: Gross Profit, 2019-2021 (US$ million, AGR %)
Figure 218 Teva: R&D, 2019-2021 (US$ million, AGR %)
Figure 219 BMS: Net Revenue, 2019-2021 (US$ million, AGR %)
Figure 220 BMS: Regional Market Shares, 2021
Figure 221 BMS: Net Earnings, 2019-2021 (US$ million, AGR %)
Figure 222 BMS: R&D, 2019-2021 (US$ million, AGR %)
Figure 223 Arbutus Biopharma: Net Revenue, 2019-2021 (US$ million, AGR %)
Figure 224 Arbutus Biopharma: Comprehensive Loss, 2019-2021 (US$ million, AGR %)
Figure 225 Arbutus Biopharma: R&D, 2019-2021 (US$ million, AGR %)
List of Companies Profiled in the report
AbbVie
Arbustus Biopharma
BMS
Boehringer Ingelheim
Gilead Sciences
GSK
Janssen Pharmaceutical
Merck
Pfizer
Teva
List of Other Companies Mentioned in the report
Acceleron Pharma Inc.
Antios Therapeutics, Inc.
Assembly Biosciences, Inc.
Halozyme Therapeutics, Inc.
Pandion Therapeutics, Inc
Qilu Pharmaceutical
Shionogi & Co. Ltd.
Vaccitech plc
Vir Biotechnology, Inc
Wake Forest University School of Divinity
List of Associations Mentioned in the Report
Bill & Melinda Gates Foundation
CDC-Centres for Disease Control and Prevention
China Center for Disease Control
European Commission
European Medicines Agency (EMA)
Food and Drug Administration (US FDA)
Joint United Nations Programme on HIV/AIDS (UNAIDS)
Korea Centers for Disease Control and Prevention
Merck Foundation
Ministry of Health (MOH)
Ministry of Health, Labor and Welfare (MHLW)
NHS: National Health Service
NIH- National Institutes of Health
Pan American Health Organization
State Council AIDS Working Committee
World Health Organization (WHO)
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
